CROI 2017 Highlighted ACTG Network Presentations

Post Date: 
ACTG Newsletter
A5274: Impact of INH adherence on TB incidence and mortality by week 96 in REMEMBER Trial
Amita Gupta, MD, MHS, Baltimore-Washington-India Clinical Trials Unit, co-PI and Investigator, Johns Hopkins University Clinical Research Site
The A5274/REMEMBER trial team previously reported that among those with a negative TB screen (TB disease was ruled out using symptom screen and rapid microbiological diagnosis), a strategy of Empiric 4-drug TB therapy +ART provided no additional benefit in reducing mortality within 24 weeks after ART initiation compared to INH preventive therapy (IPT)+ART. ​